Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...

(Reuters) - Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and announced a dividend and stock buyback ...

This can cause the immune response that leads to eczema symptoms. Some specific problems with a part of the immune system called the adaptive immune system probably also contribute to the disease.

Dupixent is already approved in the US for a variety of indications, going back to eczema in 2017 (and most recently for the treatment of the rare skin condition prurigo nodularis), but its ...

Atopic dermatitis, also known as atopic eczema ... to current standard treatments." Sanofi to increase competition in atopic dermatitis market after Dupixent’s success - (https ...